0001778016--12-312022Q2false2022-06-3000017780162022-01-012022-06-300001778016us-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-170001778016us-gaap:MeasurementInputPriceVolatilityMember2020-12-170001778016us-gaap:MeasurementInputExercisePriceMember2020-12-170001778016us-gaap:MeasurementInputRiskFreeInterestRateMember2020-09-110001778016us-gaap:MeasurementInputPriceVolatilityMember2020-09-110001778016us-gaap:MeasurementInputExercisePriceMember2020-09-110001778016us-gaap:MeasurementInputMaturityMember2020-12-170001778016us-gaap:MeasurementInputMaturityMember2020-09-110001778016us-gaap:SeriesCPreferredStockMember2020-01-170001778016imab:SeriesCOneConvertiblePreferredStockMember2020-01-170001778016imab:ConvertiblePreferredStockSeriesB2Member2020-01-170001778016us-gaap:CommonStockMember2022-01-012022-06-300001778016imab:SpecialAwardsMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-01-012020-12-310001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2021-01-012021-12-310001778016us-gaap:PrivatePlacementMember2020-09-032020-09-030001778016us-gaap:RetainedEarningsMember2022-06-300001778016us-gaap:AdditionalPaidInCapitalMember2022-06-300001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001778016us-gaap:RetainedEarningsMember2021-12-310001778016us-gaap:AdditionalPaidInCapitalMember2021-12-310001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001778016us-gaap:RetainedEarningsMember2021-06-300001778016us-gaap:AdditionalPaidInCapitalMember2021-06-300001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001778016us-gaap:RetainedEarningsMember2020-12-310001778016us-gaap:AdditionalPaidInCapitalMember2020-12-310001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001778016us-gaap:CommonStockMember2022-06-300001778016us-gaap:CommonStockMember2021-12-310001778016us-gaap:CommonStockMember2021-06-300001778016us-gaap:CommonStockMember2020-12-310001778016dei:AdrMemberus-gaap:IPOMember2020-01-170001778016imab:EmployeeStockOptionPlanMember2022-06-300001778016dei:AdrMemberus-gaap:PrivatePlacementMember2020-09-030001778016dei:AdrMember2020-02-100001778016imab:DrzangMemberus-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2019-12-252019-12-250001778016imab:TwentyNineteenShareIncentivePlanMember2021-01-012021-12-310001778016imab:TwentyTwentyTwoEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-12-310001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-12-310001778016imab:TwentyNineteenShareIncentivePlanMember2020-01-012020-12-310001778016imab:FoundersMemberus-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2019-12-252019-12-250001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:TwentyNineteenShareIncentivePlanMember2022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyMember2022-06-300001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2021-12-310001778016imab:TwentyNineteenShareIncentivePlanMember2021-12-310001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-12-310001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2022-06-300001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:TwentyTwentyTwoEmployeeStockOptionPlanMember2022-06-170001778016imab:TwentyTwentyTwoEmployeeStockOptionPlanMember2022-06-170001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-280001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-280001778016us-gaap:RestrictedStockUnitsRSUMember2020-07-150001778016imab:ShareIncentivePlanTwoThousandTwentyMember2020-07-150001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2019-12-310001778016imab:TwentyNineteenShareIncentivePlanMember2019-10-290001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2019-02-220001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2017-10-310001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-12-310001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-12-310001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-12-310001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-12-310001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-05-282021-05-280001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-05-282021-05-280001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareBasedCompensationTrancheFourMember2021-05-282021-05-280001778016imab:SecondOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-05-282021-05-280001778016imab:SharePriceBasedAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-05-282021-05-280001778016imab:SharePriceBasedAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-05-282021-05-280001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-282021-05-280001778016imab:OnePerformanceConditionMember2021-05-282021-05-280001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:TwoPerformanceConditionsMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ThreePerformanceConditionsMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareBasedCompensationTrancheFourMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:OnePerformanceConditionMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:FourPerformanceConditionsMember2020-07-152020-07-150001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-07-152020-07-150001778016imab:TwentyEighteenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-02-222019-02-220001778016imab:TwentyEighteenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2019-02-222019-02-220001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2017-10-012017-10-310001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2017-10-012017-10-310001778016imab:SharePriceBasedAwardsMember2021-05-282021-05-280001778016us-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2019-02-222019-02-220001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2017-10-012017-10-310001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:SpecialAwardsMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016imab:PaycheckProtectionMember2022-01-012022-06-300001778016imab:PaycheckProtectionMember2021-01-012021-06-300001778016imab:SupplyOfInvestigationalProductsMember2022-01-012022-06-300001778016imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember2022-01-012022-06-300001778016imab:LicensingAndCollaborationMember2022-01-012022-06-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2021-01-012021-12-310001778016imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember2021-01-012021-12-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2021-01-012021-06-300001778016imab:LicensingAndCollaborationMember2021-01-012021-06-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2020-01-012020-12-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2019-01-012019-12-310001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:ABLBioMemberimab:CollaborationAgreementWithABLBioMember2022-01-012022-06-300001778016imab:ABLBioMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:CollaborationAgreementWithABLBioMember2022-01-012022-06-300001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2022-01-012022-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:ABLBioMemberimab:CollaborationAgreementWithABLBioMember2021-01-012021-06-300001778016imab:GenexineIncMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithGenexineIncMember2021-01-012021-06-300001778016imab:ABLBioMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:CollaborationAgreementWithABLBioMember2021-01-012021-06-300001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2021-01-012021-06-300001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2021-01-012021-06-300001778016imab:Study2Memberimab:AbbVieMember2020-12-102020-12-100001778016imab:Study1Memberimab:AbbVieMember2020-12-102020-12-100001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2020-01-012020-12-310001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2019-01-012019-12-310001778016srt:MinimumMemberimab:SoftwareMember2022-01-012022-06-300001778016srt:MinimumMemberimab:LaboratoryEquipmentMember2022-01-012022-06-300001778016srt:MaximumMemberimab:SoftwareMember2022-01-012022-06-300001778016srt:MaximumMemberimab:LaboratoryEquipmentMember2022-01-012022-06-300001778016us-gaap:TransportationEquipmentMember2022-01-012022-06-300001778016imab:OfficeFurnitureAndEquipmentMember2022-01-012022-06-300001778016us-gaap:TransportationEquipmentMember2022-06-300001778016us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-06-300001778016us-gaap:OfficeEquipmentMember2022-06-300001778016us-gaap:LeaseholdImprovementsMember2022-06-300001778016imab:LaboratoryEquipmentMember2022-06-300001778016us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001778016us-gaap:OfficeEquipmentMember2021-12-310001778016us-gaap:LeaseholdImprovementsMember2021-12-310001778016imab:LaboratoryEquipmentMember2021-12-310001778016srt:MaximumMemberimab:AbbVieMember2020-09-032020-09-030001778016imab:ClinicalMilestonesMemberimab:AbbVieMember2020-09-032020-09-030001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2019-09-012019-09-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2019-02-012019-02-280001778016imab:InvestorWarrantsMemberdei:AdrMember2020-09-032020-09-030001778016dei:AdrMember2020-02-102020-02-100001778016dei:AdrMemberus-gaap:IPOMember2020-01-172020-01-170001778016imab:SeriesAConvertiblePreferredStockMember2020-01-170001778016imab:ConvertiblePreferredStockSeriesBOneUponConversionMember2020-01-170001778016imab:ConvertiblePreferredStockSeriesBMember2020-01-170001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001778016us-gaap:RetainedEarningsMember2022-01-012022-06-300001778016us-gaap:RetainedEarningsMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:IMabHangzhouShareBasedCompensationMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:HLBVMethodMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:GroupsShareBasedCompensationMember2022-01-012022-06-300001778016imab:PartnershipAgreementMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:IMabHangzhouShareBasedCompensationMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:HLBVMethodMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:GroupsShareBasedCompensationMember2021-01-012021-06-300001778016imab:PartnershipAgreementMember2021-01-012021-06-300001778016imab:LongTermInvestmentUnderEquityMethodMember2022-01-012022-06-300001778016imab:LongTermInvestmentUnderEquityMethodMember2021-01-012021-06-300001778016imab:PeoplesBankOfChinaMember2022-06-300001778016imab:FederalReserveBankOfNewYorkMember2022-06-300001778016imab:PeoplesBankOfChinaMember2021-12-310001778016srt:MinimumMemberus-gaap:ContractBasedIntangibleAssetsMember2022-01-012022-06-300001778016srt:MaximumMemberus-gaap:ContractBasedIntangibleAssetsMember2022-01-012022-06-300001778016imab:IprAndDTj101Member2022-06-300001778016imab:IprAndDTj101Member2021-12-310001778016imab:TJ103Member2022-06-300001778016imab:TJ103Member2021-12-310001778016us-gaap:InvestmentsMember2022-06-300001778016imab:PutRightLiabilitiesMember2022-06-300001778016us-gaap:InvestmentsMember2021-12-310001778016imab:PutRightLiabilitiesMember2021-12-310001778016imab:PartnershipAgreementMember2022-06-300001778016imab:PartnershipAgreementMember2021-12-310001778016imab:ImabHangzhouMember2021-12-310001778016imab:PartnershipAgreementMember2021-08-3100017780162020-09-012020-09-300001778016imab:ZhejiangTianliPharmaceuticalSalesCoLtdMember2022-06-300001778016imab:IMabtianjinMember2022-06-300001778016imab:IMabShanghaiMember2022-06-300001778016imab:ImabHangzhouMember2022-06-300001778016imab:ImabbiopharmaUsLtdMember2022-06-300001778016imab:IMabBiopharmaHongKongLimitedMember2022-06-300001778016imab:ImabHangzhouMemberimab:ImabHongKongMember2020-12-310001778016imab:ImabHangzhouMemberimab:EsopHoldcoMember2020-12-310001778016imab:ImabHangzhouMemberimab:DomesticInvestorsMember2020-12-310001778016dei:AdrMember2022-01-012022-06-300001778016dei:AdrMember2021-01-012021-06-300001778016imab:ImabHangzhouMember2022-06-300001778016imab:AbbVieMember2022-01-012022-06-300001778016imab:AbbVieMember2021-01-012021-12-310001778016imab:AbbVieMember2021-01-012021-06-300001778016imab:EverestsMemberimab:CollaborationAgreementWithEverestMember2020-01-170001778016us-gaap:SeriesCPreferredStockMember2020-01-172020-01-170001778016imab:SeriesCOneConvertiblePreferredStockMember2020-01-172020-01-170001778016imab:SeriesAConvertiblePreferredStockMember2020-01-172020-01-170001778016imab:ConvertiblePreferredStockSeriesBOneUponConversionMember2020-01-172020-01-170001778016imab:ConvertiblePreferredStockSeriesBMember2020-01-172020-01-170001778016imab:ConvertiblePreferredStockSeriesB2Member2020-01-172020-01-170001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2018-12-310001778016imab:AbbVieMember2022-06-300001778016imab:AbbVieMember2020-12-310001778016imab:PartnershipAgreementMember2021-07-310001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2020-12-310001778016imab:ImabHongKongMember2021-06-300001778016imab:ImabHangzhouMember2021-06-300001778016imab:DomesticInvestorsMember2021-06-300001778016imab:ImabHongKongMember2020-12-310001778016imab:ImabHangzhouMember2020-12-310001778016imab:DomesticInvestorsMember2020-12-3100017780162019-12-3100017780162018-12-310001778016imab:FoundersMemberus-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2019-12-250001778016imab:DrzangMemberus-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2019-12-250001778016imab:InvestorWarrantsMemberdei:AdrMember2020-09-030001778016imab:InvestorWarrantsMember2020-09-030001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-12-170001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-09-1100017780162021-06-3000017780162020-12-310001778016imab:ImabHangzhouMember2022-06-300001778016imab:TasgenGroupMember2017-07-150001778016us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOtherMember2022-06-300001778016imab:ImabHangzhouMember2022-06-300001778016us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOtherMember2021-12-310001778016imab:ImabHangzhouMember2021-12-310001778016us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001778016us-gaap:WarrantMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001778016imab:TJ103Member2022-01-012022-06-300001778016imab:TJ103Member2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001778016imab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016imab:EquityInLossOfAnAffiliateMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016imab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMember2021-01-012021-06-300001778016srt:MinimumMember2022-01-012022-06-300001778016srt:MaximumMember2022-01-012022-06-300001778016srt:MaximumMemberimab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember2020-03-012020-03-310001778016imab:AbbVieMember2020-01-012020-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2022-01-012022-06-300001778016imab:OtherInLicensingArrangementMember2022-01-012022-06-300001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2021-01-012021-12-310001778016imab:AbbVieMember2020-09-032020-09-030001778016imab:MacroGenicsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMacroGenicsMember2019-01-012019-12-310001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementsWithMorphosysMember2018-01-012018-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2018-01-012018-12-310001778016imab:GenexineIncMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithGenexineIncMember2018-01-012018-01-310001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2017-01-012017-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2017-01-012017-12-310001778016imab:LemzoparlimabLicenseMemberimab:AbbVieMember2022-01-012022-06-300001778016imab:LemzoparlimabLicenseMemberimab:AbbVieMember2021-01-012021-12-310001778016imab:AbbVieMember2020-12-102020-12-100001778016imab:MacroGenicsMemberus-gaap:SubsequentEventMemberimab:LicensingAgreementWithMacroGenicsMember2022-08-292022-08-290001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2021-06-300001778016imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2021-02-280001778016imab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-06-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2022-01-312022-01-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2022-01-012022-06-300001778016imab:SecondMilestoneMemberimab:MorphosysMemberimab:LicensingAgreementsWithMorphosysMember2021-01-012021-01-310001778016imab:SecondMilestoneMemberimab:LicensingAgreementsWithMorphosysMember2021-01-012021-01-310001778016imab:ImabHangzhouMemberimab:DomesticInvestorsMember2020-09-150001778016imab:ImabHangzhouMember2020-09-150001778016imab:ImabHangzhouMember2019-06-160001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2020-09-150001778016imab:ImabHangzhouMemberimab:EsopHoldcoMember2020-09-150001778016us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001778016us-gaap:FairValueMeasurementsRecurringMember2022-06-300001778016us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001778016us-gaap:FairValueMeasurementsRecurringMember2021-12-310001778016us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-3000017780162021-11-3000017780162020-04-012020-04-300001778016dei:AdrMemberus-gaap:PrivatePlacementMember2020-09-032020-09-030001778016imab:CollaborationAgreementWithInvestorsMember2020-09-032020-09-030001778016imab:ImabHangzhouMember2021-12-310001778016imab:BoardOfDirectorsMemberdei:AdrMember2020-07-150001778016imab:GenexineIncMemberimab:Gxi7Memberimab:LicensingAgreementWithGenexineIncMember2018-01-012018-01-310001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementsWithMorphosysMember2021-01-012021-06-300001778016imab:ImabHangzhouMember2022-01-012022-06-300001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-07-152020-07-150001778016imab:RegulatoryMilestoneMemberimab:MacroGenicsMembersrt:MaximumMemberus-gaap:LicensingAgreementsMemberimab:LicensingAgreementWithMacroGenicsMember2022-01-012022-06-300001778016imab:DevelopmentMilestoneMembersrt:MaximumMemberimab:MacroGenicsMemberimab:LicensingAgreementWithMacroGenicsMember2022-01-012022-06-300001778016imab:SecondMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2022-01-012022-06-300001778016imab:GenexineIncMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:GenexineIncMemberimab:Gxi7Memberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:FirstMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2022-01-012022-06-300001778016imab:SalesMilestonesMemberimab:OtherInLicensingArrangementMember2022-01-012022-06-300001778016imab:MorphosysMemberimab:LicensingAgreementsWithMorphosysMember2022-01-012022-06-300001778016imab:MacroGenicsMemberimab:LicensingAgreementWithMacroGenicsMember2022-01-012022-06-300001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:DevelopmentMilestoneMemberimab:OtherInLicensingArrangementMember2022-01-012022-06-300001778016imab:FirstMilestoneMemberimab:MacroGenicsMemberimab:LicensingAgreementWithMacroGenicsMember2021-09-012021-09-300001778016imab:SecondMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2021-01-012021-12-310001778016imab:FirstMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2021-01-012021-12-310001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2021-01-012021-12-310001778016imab:MacroGenicsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMacroGenicsMember2021-01-012021-06-300001778016imab:OtherInLicensingArrangementMember2021-01-012021-06-300001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementsWithMorphosysMember2020-01-012020-12-310001778016imab:MacroGenicsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMacroGenicsMember2020-01-012020-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2019-01-012019-12-310001778016imab:MorphosysMemberimab:LicensingAgreementsWithMorphosysMember2019-01-012019-12-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2018-01-012018-12-310001778016imab:MorphoSysAGMemberimab:LicensingAgreementWithMorphosysAgMember2017-11-172017-11-170001778016imab:AbbVieMember2021-03-310001778016imab:SecondOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-282021-05-280001778016imab:SecondOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-07-152020-07-150001778016imab:SecondClosingPeriodMemberimab:HillhouseEntitiesMember2020-12-172020-12-170001778016imab:FirstClosingPeriodMemberimab:HillhouseEntitiesMember2020-09-112020-09-110001778016us-gaap:InvestmentsMember2022-01-012022-06-300001778016imab:PutRightLiabilitiesMember2022-01-012022-06-3000017780162021-01-012021-12-310001778016imab:ImabHangzhouMember2021-06-300001778016srt:MaximumMemberus-gaap:SubsequentEventMemberimab:AmendmentToOriginalLicensingAndCollaborationAgreementMember2022-07-012022-12-3100017780162020-09-032020-09-030001778016imab:ABLBioMemberus-gaap:OperatingExpenseMemberimab:CollaborationAgreementWithABLBioMember2022-01-012022-06-300001778016imab:JumpcanAgreementMember2021-01-012021-12-310001778016imab:ABLBioMemberus-gaap:OperatingExpenseMemberimab:CollaborationAgreementWithABLBioMember2021-01-012021-06-300001778016imab:Study2Memberimab:AbbVieMember2022-01-012022-06-300001778016imab:Study1Memberimab:AbbVieMember2022-01-012022-06-300001778016imab:Study2Memberimab:AbbVieMember2021-01-012021-06-300001778016imab:Study1Memberimab:AbbVieMember2021-01-012021-06-300001778016imab:Study2Memberimab:AbbVieMember2020-01-012020-12-310001778016imab:Study1Memberimab:AbbVieMember2020-01-012020-12-310001778016us-gaap:InvestorMember2019-10-290001778016dei:AdrMemberus-gaap:OverAllotmentOptionMember2020-02-100001778016imab:HillhouseEntitiesMember2022-01-012022-06-300001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-12-172020-12-170001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-09-112020-09-110001778016imab:ImabHangzhouMemberimab:DomesticInvestorsMember2020-09-152020-09-150001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2020-09-152020-09-150001778016imab:ImabHangzhouMember2021-01-012021-06-300001778016imab:JumpcanAgreementMember2022-01-012022-06-300001778016us-gaap:CommonStockMember2021-01-012021-06-300001778016us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-3000017780162021-01-012021-06-3000017780162022-06-3000017780162021-12-3100017780162020-02-100001778016imab:ZhejiangTianliPharmaceuticalSalesCoLtdMember2022-01-012022-06-300001778016imab:IMabtianjinMember2022-01-012022-06-300001778016imab:IMabShanghaiMember2022-01-012022-06-300001778016imab:ImabbiopharmaUsLtdMember2022-01-012022-06-300001778016imab:IMabBiopharmaHongKongLimitedMember2022-01-012022-06-30xbrli:pureiso4217:CNYiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesiso4217:CNYxbrli:sharesiso4217:USDiso4217:CNYimab:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2022

--------------

Commission File Number: 001-39173

----------

I-MAB

55th – 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District

Shanghai, 200124

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXPLANATORY NOTE

Exhibits 99.1, 99.2 and 99.3 to this current report on Form 6-K are incorporated by reference into the registration statement on Form F-3 of I-Mab (File No. 333-252793) and shall be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.

Description

99.1

Unaudited Condensed Consolidated Interim Financial Statements

99.2

Discussion of Unaudited Financial Statements

99.3

Recent Developments

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

I-MAB

By       :

/s/ Richard Yeh

Name  :

Richard Yeh

Title    :

Chief Operating Officer and Interim Chief Financial Officer

Date: November 10, 2022